Author: Stami Turk
Making the best decision about which medicines to take should be a decision between patients and their doctors, not unelected bureaucrats. Price-setting boards, such as the prescription drug affordability board (PDAB) being proposed in Virginia, ignore this principle and threaten access to life-saving medicines.
Here’s why:
Patient groups across the country have publicly shared their concern that PDABs may reduce access to medicines. And they’ve been joined by voices across the supply chain including hospitals, insurers, and doctors. These voices expose real and unfortunate potential consequences to government price-setting. Ask patients in Colorado suffering from Cystic Fibrosis who had their vital access to medicines threatened by the PDAB.
The focus should be on real reform, not bureaucratic overreach. Instead of price-setting boards, we need solutions that address systemic issues with insurers and PBMs and improve access to life-saving medicines. Virginia lawmakers are urged to vote NO on HB 1724.
©2024 Pharmaceutical Research and Manufacturers of America, 670 Maine Avenue, SW, Suite 1000, Washington, DC 20024
Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how we and third parties use pixel tags, and how that use affects you, click here.